Edition:
United States

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

133.85USD
14 Dec 2018
Change (% chg)

$2.43 (+1.85%)
Prev Close
$131.42
Open
$130.63
Day's High
$134.56
Day's Low
$129.23
Volume
159,672
Avg. Vol
174,529
52-wk High
$220.09
52-wk Low
$92.20

Latest Key Developments (Source: Significant Developments)

Beigene Presents Preliminary Clinical Trial Data In Patients With Solid Tumors
Monday, 22 Oct 2018 07:15am EDT 

Oct 22 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE PRESENTS PRELIMINARY CLINICAL DATA ON PARP INHIBITOR PAMIPARIB IN COMBINATION WITH LOW-DOSE TEMOZOLOMIDE IN PATIENTS WITH SOLID TUMORS AT EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) 2018 CONGRESS.BEIGENE LTD - TWO PATIENTS EXPERIENCED AES RESULTING IN DISCONTINUATION OF PAMIPARIB AND TMZ, ONE CONSIDERED RELATED TO STUDY TREATMENT.BEIGENE LTD - PRELIMINARY RESULTS, SAFETY AND TOLERABILITY PROFILE, SUPPORT CONTINUED DEVELOPMENT OF THE COMBINATION.  Full Article

MEI Pharma And Beigene Announce Clinical Collaboration
Thursday, 11 Oct 2018 06:00am EDT 

Oct 11 (Reuters) - Beigene Ltd <6160.HK>::MEI PHARMA AND BEIGENE ANNOUNCE CLINICAL COLLABORATION TO EVALUATE ME-401 IN COMBINATION WITH ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES.MEI PHARMA INC - STUDY COSTS WILL BE SHARED EQUALLY BY PARTIES, AND MEI WILL SUPPLY ME-401 AND BEIGENE WILL SUPPLY ZANUBRUTINIB.MEI PHARMA INC - UNDER TERMS OF CLINICAL COLLABORATION AGREEMENT, MEI WILL AMEND ITS ONGOING PHASE 1B TRIAL.MEI PHARMA INC - WILL RETAIN FULL COMMERCIAL RIGHTS FOR ME-401 & BEIGENE WILL RETAIN FULL COMMERCIAL RIGHTS FOR ZANUBRUTINIB.MEI PHARMA - AMENDMENT OF ONGOING PHASE 1B TRIAL TO INCLUDE EVALUATION OF ME-401 IN COMBINATION WITH ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES.  Full Article

Beigene Announces Preliminary Results From The Phase 1 Clinical Trial Of Zanubrutinib
Friday, 21 Sep 2018 08:30pm EDT 

Sept 21 (Reuters) - Beigene Ltd 6160.HK::BEIGENE ANNOUNCES PRELIMINARY RESULTS FROM THE PHASE 1 CLINICAL TRIAL OF ZANUBRUTINIB IN CHINESE PATIENTS WITH B-CELL LYMPHOMA AT ANNUAL MEETING OF THE CHINESE SOCIETY OF CLINICAL ONCOLOGY.BEIGENE LTD - NEW DRUG APPLICATION FILING FOR ZANUBRUTINIB IN CHINA IS CURRENTLY UNDER REVIEW BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA.BEIGENE -PRELIMINARY FINDINGS SUGGESTED THERE WAS NO SIGNIFICANT DIFFERENCE IN PHARMACOKINETIC PROFILE OF ZANUBRUTINIB BETWEEN CHINESE AND NON-CHINESE PATIENTS.BEIGENE LTD - NO DEATHS RELATED TO ADVERSE EVENTS WERE OBSERVED IN THE TRIAL.  Full Article

Beigene And Springworks Therapeutics Collaborate To Evaluate Targeted Combination Therapy In Advanced Solid Tumors
Thursday, 6 Sep 2018 06:00am EDT 

Sept 6 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE AND SPRINGWORKS THERAPEUTICS ENTER INTO GLOBAL CLINICAL COLLABORATION TO EVALUATE TARGETED COMBINATION THERAPY IN ADVANCED SOLID TUMORS.BEIGENE LTD - BEIGENE'S RAF DIMER INHIBITOR LIFIRAFENIB (BGB-283) AND SPRINGWORKS THERAPEUTICS' MEK INHIBITOR PD-0325901 TO BE STUDIED IN COMBINATION.BEIGENE LTD - COMBINATION APPROACH WILL TARGET RAS MUTATIONS COMMON IN MANY CANCERS IN COLLABORATION.BEIGENE LTD - PHASE 1B CLINICAL STUDY EXPECTED TO COMMENCE IN Q1 OF 2019.BEIGENE LTD - PHASE 1B CLINICAL STUDY EXPECTED TO COMMENCE IN Q1 OF 2019.BEIGENE LTD - BEIGENE WILL BE RESPONSIBLE FOR ADMINISTERING PHASE 1B CLINICAL TRIAL.  Full Article

Beigene Announces Acceptance Of NDA For Tislelizumab In Hodgkin’s Lymphoma In China
Friday, 31 Aug 2018 06:00am EDT 

Aug 31 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE ANNOUNCES ACCEPTANCE OF NEW DRUG APPLICATION FOR ANTI-PD-1 ANTIBODY TISLELIZUMAB IN HODGKIN’S LYMPHOMA IN CHINA.BEIGENE - NMPA ACCEPTED NDA FOR TISLELIZUMAB AS POTENTIAL TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA.  Full Article

Shares Of Beigene Set To Open On Hong Kong Debut Flat At HK$108.00
Tuesday, 7 Aug 2018 08:00pm EDT 

Aug 8 (Reuters) - Beigene Ltd <6160.HK>::SET TO OPEN ON HONG KONG DEBUT AT HK$108.00 VERSUS HK$108.00 ISSUE PRICE.  Full Article

Beigene Anticipates That The Public Offering Price Will Be Between Hk$94.40 And Hk$111.60 Per Share, Or Between About $12.03 And $14.22 Per
Friday, 27 Jul 2018 08:19am EDT 

July 27 (Reuters) - Beigene Ltd ::BEIGENE LTD - ANTICIPATE THAT THE PUBLIC OFFERING PRICE WILL BE BETWEEN HK$94.40 AND HK$111.60 PER SHARE, OR BETWEEN ABOUT $12.03 AND $14.22 PER.BEIGENE LTD - HAVE APPLIED TO LIST ORDINARY SHARES ON THE STOCK EXCHANGE OF HONG KONG LIMITED, OR HKEX, UNDER THE STOCK CODE "6160".BEIGENE LTD - EXPECT TO USE NET PROCEEDS FROM THE OFFERING FOR CLINICAL TRIALS, PREPARATION FOR REGISTRATION FILINGS.BEIGENE LTD - ALSO EXPECT TO USE THE NET PROCEEDS FROM OFFERING FOR LAUNCH, COMMERCIALIZATION OF ZANUBRUTINIB, TISLELIZUMAB AND PAMIPARIB - SEC FILING.BEIGENE LTD - ANTICIPATE PUBLIC OFFERING PRICE WILL BE HK$94.40-HK$111.60 PER SHARE, OR ABOUT $12.03-$14.22 PER SHARE (ADDS DROPPED WORD 'SHARE').  Full Article

Beigene Announces Proposed Hong Kong Initial Public Offering And Global Offering
Friday, 27 Jul 2018 07:08am EDT 

July 27 (Reuters) - Beigene Ltd ::BEIGENE ANNOUNCES PROPOSED HONG KONG INITIAL PUBLIC OFFERING AND GLOBAL OFFERING.BEIGENE LTD - ANNOUNCED A HONG KONG INITIAL PUBLIC OFFERING AND A GLOBAL OFFERING OF 65.6 MILLION OF ITS ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE.BEIGENE LTD - EACH ADS REPRESENTS RIGHT TO RECEIVE 13 ORDINARY SHARES.BEIGENE LTD - OFFERING INITIALLY COMPRISES 5.9 MILLION SHARES FOR SUBSCRIPTION BY PUBLIC IN HONG KONG AND 59.7 MILLION SHARES FOR SUBSCRIPTION GLOBALLY.BEIGENE LTD - PROPOSED LISTING OF SHARES ON MAIN BOARD OF STOCK EXCHANGE OF HONG KONG LIMITED.BEIGENE LTD - UNDER OFFERING, EXPECTS TO GRANT JOINT GLOBAL COORDINATORS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 9.8 MILLION SHARES.BEIGENE - MORGAN STANLEY & CO. INTERNATIONAL PLC, GOLDMAN SACHS (ASIA) L.L.C., AMONG OTHERS, ACTING AS JOINT GLOBAL COORDINATORS FOR OFFERING.BEIGENE LTD - CREDIT SUISSE (HONG KONG) LIMITED AND CLSA LIMITED ARE ALSO ACTING AS JOINT GLOBAL COORDINATORS FOR OFFERING.  Full Article

Beigene Presents Clinical Data On Pamiparib In Chinese Patients With Ovarian Cancers At The American Association For Cancer Research Annual Meeting
Monday, 16 Apr 2018 09:00am EDT 

April 16 (Reuters) - Beigene Ltd ::BEIGENE PRESENTS CLINICAL DATA ON PAMIPARIB IN CHINESE PATIENTS WITH OVARIAN CANCERS OR TRIPLE-NEGATIVE BREAST CANCER AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING.BEIGENE LTD - PAMIPARIB WAS SHOWN TO BE GENERALLY WELL TOLERATED.BEIGENE LTD - LOOK FORWARD TO ADVANCING PAMIPARIB'S DEVELOPMENT IN CHINA AS WELL AS INITIATING A GLOBAL PHASE 3 TRIAL.BEIGENE - IN PATIENTS WITH OVARIAN, BREAST CANCER, PRELIM RESULTS SUPPORT RECOMMENDED PAMIPARIB DOSING REGIMEN, DEMONSTRATED ANTITUMOR ACTIVITY.BEIGENE-SAW NO DOSE-LIMITING TOXICITIES, FOUND PAMIPARIB TO BE GENERALLY WELL TOLERATED AMONG THE PRE-TREATED PATIENTS WITH OVARIAN, BREAST CANCERS.  Full Article

Beigene Announces Proposed Public Offering
Tuesday, 16 Jan 2018 04:04pm EST 

Jan 16 (Reuters) - Beigene Ltd ::BEIGENE ANNOUNCES PROPOSED PUBLIC OFFERING.BEIGENE LTD - ‍PUBLIC OFFERING OF ITS AMERICAN DEPOSITARY SHARES (ADSS), EACH REPRESENTING 13 OF ITS ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE​.BEIGENE LTD - ‍BEIGENE INTENDS TO OFFER AND SELL $650 MILLION OF ITS ADSS, BEFORE UNDERWRITING DISCOUNTS AND COMMISSIONS AND ESTIMATED OFFERING EXPENSES​.  Full Article

Photo

Chinese biotech BeiGene raises $903 million in HK's first secondary listing under new rules: sources

HONG KONG (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.